US Biosimilars Take A Bite Out Of Roche's Herceptin, But Tecentriq Surges
Risdiplam Launch Among 2020 Tests
Executive Summary
Roche's Q4 and full year results are slightly below expectations, but analysts still see it as one of sector's strong performers in 2020.
You may also be interested in...
Zolgensma Stands Out In Strong Q4 For Novartis
CEO Vas Narasimhan is confident the Swiss major's gene therapy for spinal muscular atrophy will outperform present and future rivals – Biogen's Spinraza and Roche's risdiplam, respectively – as "we have a better profile simply because we are a one-time therapy."
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.
Vertex Joins Regulus In Kidney Disease Therapy Hunt
The Boston, MA biotech is about to enter the clinic with its autosomal dominant polycystic kidney disease candidate but microRNA therapy pioneer Regulus is already setting the pace.